Unibest

Pharmaceutical intermediates

Repotrectinib Intermediates

2 pharmaceutical intermediates for Repotrectinib. Indication: Solid tumors; non-small cell lung cancer.

提交项目All intermediates

About Repotrectinib

Originator
Turning Point Therapeutics Inc
Indication
Solid tumors; non-small cell lung cancer
Approved Date
06/11/2024
NCE Patent
11/15/2028
DS/DP
01/23/2035

Available intermediates

2 intermediates currently listed for Repotrectinib. Request specifications, documentation or a quotation for any item below.

Repotrectinib intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
Ethyl 5-chloropyrazolo[1,5-a]pyrimidine-3-carboxylate1224944-77-7//
Pentafluorophenyldiphenylphosphinate138687-69-1//

Other programs under R

Ramelteon RegorafenibRelugolixRemdesivir RemibrutinibResmetiromRevumenibRibociclib Succinate

Building toward Repotrectinib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →